株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

変性脊椎すべり症:世界の治験動向

Degenerative Spondylolisthesis Global Clinical Trials Review, H2, 2017

発行 GlobalData 商品コード 306659
出版日 ページ情報 英文 49 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.40円で換算しております。
Back to Top
変性脊椎すべり症:世界の治験動向 Degenerative Spondylolisthesis Global Clinical Trials Review, H2, 2017
出版日: 2017年07月26日 ページ情報: 英文 49 Pages
概要

当レポートでは、変性脊椎すべり症に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、G7およびE7諸国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んでお届けします。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 主要国における治験件数; アジア太平洋地域
    • 上位5ヶ国における治験件数; 欧州
    • 主要国における治験件数; 北米

G7諸国における治験件数:変性脊椎すべり症治験件数の筋骨格障害治験件数に対する比率

フェーズ(相)別治験件数: G7諸国

G7諸国における治験件数:フェーズ(相)別

E7諸国における治験件数:変性脊椎すべり症治験件数の筋骨格障害治験件数に対する比率

E7諸国における治験件数:フェーズ(相)別

フェーズ(相)別治験件数

  • フェーズ(相)別の進行中治験件数

進捗状況別の治験件数

評価項目別の治験件数

一定期間に採用された被験者数

スポンサーの種類別治験件数

有望なスポンサー

治験主要参加企業 - 変性脊椎すべり症治療薬

有望な薬剤

治験プロファイルの基本情報

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC4365CTIDB

GlobalData's clinical trial report, "Degenerative Spondylolisthesis Global Clinical Trials Review, H2, 2017" provides an overview of Degenerative Spondylolisthesis clinical trials scenario. This report provides top line data relating to the clinical trials on Degenerative Spondylolisthesis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Clinical Trials by G7 Countries: Proportion of Degenerative Spondylolisthesis to Musculoskeletal Disorders Clinical Trials 14
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Degenerative Spondylolisthesis to Musculoskeletal Disorders Clinical Trials 18
  • Clinical Trials by Phase 20
  • In Progress Trials by Phase 21
  • Clinical Trials by Trial Status 22
  • Clinical Trials by End Point Status 23
  • Subjects Recruited Over a Period of Time 24
  • Clinical Trials by Sponsor Type 25
  • Prominent Sponsors 26
  • Top Companies Participating in Degenerative Spondylolisthesis Therapeutics Clinical Trials 28
  • Prominent Drugs 30
  • Clinical Trial Profile Snapshots 31

Appendix 47

  • Abbreviations 47
  • Definitions 47
  • Research Methodology 48
  • Secondary Research 48
  • About GlobalData 49
  • Contact Us 49
  • Source 49

List of Tables

List of Tables

  • Degenerative Spondylolisthesis Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Degenerative Spondylolisthesis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Degenerative Spondylolisthesis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Degenerative Spondylolisthesis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 11
  • Degenerative Spondylolisthesis Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Degenerative Spondylolisthesis Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Proportion of Degenerative Spondylolisthesis to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2017* 15
  • Degenerative Spondylolisthesis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Degenerative Spondylolisthesis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Degenerative Spondylolisthesis to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2017* 19
  • Degenerative Spondylolisthesis Therapeutics, Global, Clinical Trials by Phase, 2017* 20
  • Degenerative Spondylolisthesis Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 21
  • Degenerative Spondylolisthesis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 22
  • Degenerative Spondylolisthesis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 23
  • Degenerative Spondylolisthesis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 24
  • Degenerative Spondylolisthesis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 25
  • Degenerative Spondylolisthesis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
  • Degenerative Spondylolisthesis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Degenerative Spondylolisthesis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30

List of Figures

List of Figures

  • Degenerative Spondylolisthesis Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Degenerative Spondylolisthesis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Degenerative Spondylolisthesis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Degenerative Spondylolisthesis Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2017* 11
  • Degenerative Spondylolisthesis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
  • Proportion of Degenerative Spondylolisthesis to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2017* 14
  • Degenerative Spondylolisthesis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Degenerative Spondylolisthesis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Degenerative Spondylolisthesis to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2017* 18
  • Degenerative Spondylolisthesis Therapeutics, Global, Clinical Trials by Phase (%), 2017* 20
  • Degenerative Spondylolisthesis Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 21
  • Degenerative Spondylolisthesis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 22
  • Degenerative Spondylolisthesis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 23
  • Degenerative Spondylolisthesis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 24
  • Degenerative Spondylolisthesis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 25
  • Degenerative Spondylolisthesis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 26
  • Degenerative Spondylolisthesis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
  • Degenerative Spondylolisthesis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30
  • GlobalData Methodology 48
Back to Top